###### Key messages

What is already known about this subject?
=========================================

Cardiovascular disease is the leading cause of death in smokers and this relationship is complicated by the multiplicity of cardiovascular effects of smoking. Traditionally, pack-years has been a standard clinical history assessment of total tobacco exposure.

What does this study add?
=========================

With this study, there is evidence that there are cardiac abnormalities of structure and function associated with the intensity and duration of cigarette use in a relatively young cohort which could serve as important data for clinicians to use when counselling their patients on tobacco cessation.

How might this impact on clinical practice?
===========================================

Cigarette smoking exposure may impact the development of cardiomyopathy in a direct, continuous dose-dependent fashion and thus may contribute to the heart failure epidemic. The potential contribution of tobacco exposure to cardiomyopathy development deserves further study and public health vigilance.

Introduction {#s1}
============

Cigarette smoking is a well-known and preventable risk factor for atherosclerotic cardiovascular disease.[@R1] The American Heart Association has identified abstaining from or quitting cigarette smoking as a major component of cardiovascular health.[@R2] Over the past few decades, the rate of cigarette smoking in adults has decreased in the United States but still remains significant at 16.8%.[@R3] Whereas the decreasing rates are encouraging, there are approximately 40 million adults still smoking cigarettes. In 2014, 10.7% of Hispanics/Latinos were current smokers and an additional 16.5% were former smokers.[@R4]

The relationship between cardiovascular disease and tobacco use is complicated by the multiplicity of the cardiovascular effects that are a result of smoking. In addition to atherosclerosis, the smoking status has been associated with structural changes in the heart including increasing left ventricle (LV) mass and abnormal LV geometry compared with non-smokers even after excluding those with major cardiovascular events such as interim atrial fibrillation and myocardial infarction.[@R5] Research in the same cohort also found that current smoking status was associated with higher mean left atrium diameter.[@R6]

The relation of cigarette use with cardiac function has been less studied. Furthermore, while cigarette smoking or tobacco usage has generally been examined as a binary (yes/no) covariate, few major cohorts have assessed duration and intensity of cigarette use and their association with right and left ventricular cardiac structure and function via echocardiography. We hypothesised that younger age of smoking initiation (longer duration), increased number of cigarettes smoked per day (higher intensity) and total pack-years (an index of combined duration and intensity) would be associated with worse parameters of right-sided and left-sided cardiac structure and function.

Methods {#s2}
=======

The Hispanic Community Health Study/Study of Latinos (HCHS/SOL) is a population-based longitudinal cohort study designed to examine multiple aspects of chronic disease affecting the Hispanic/Latino population of the United States. Details of study design and sample selection have been published previously.[@R7] Briefly, Hispanics/Latinos (n=16 415) aged 18--74 years and residing in four US metropolitan areas (Bronx, NY; Chicago, IL; Miami, FL; and San Diego, CA) were recruited between 2008 and 2011. Ineligibility criteria for the HCHS/SOL included being on active military service, not currently living at home, planning to move from the area in the next 6 months, unable to complete the study in English or Spanish, or unable to attend the clinic examination.

ECHO-SOL (Echocardiographic Study of Hispanics/Latinos) was designed to provide echocardiographic measures characterising cardiac structure and function in a representative baseline subsample of the HCHS/SOL. The ECHO-SOL used a stratified sampling design to assure that ECHO-SOL represented the Hispanic subgroup distribution found in each of four HCHS/SOL field centres. A detailed description of the design, rationale and methods has been described elsewhere.[@R9] Eligibility criteria for inclusion in ECHO-SOL were: aged 45 years or older and having completed the HCHS/SOL baseline visit within 36 months or less from the date of enrolment. The Institutional Review Board at Wake Forest School of Medicine and at each field centre provided approval and oversight of all study materials and activities.

Smoking assessment {#s2a}
------------------

Study examinations included completion of standardised clinical measurements and questionnaires, conducted between 2008 and 2011 by a bilingual interviewer in either English or Spanish. Lifetime history of cigarette smoking was elicited by the question, 'Have you ever smoked at least 100 cigarettes in your entire life?'. Other smoking-related variables included number of cigarettes per day, age at smoking initiation and periods of smoking cessation. Self-reported information was used to define current daily smokers, and to define intermittent or some-days smokers as current smokers who did not report using cigarettes on a daily basis. Among current daily smokers, we estimated lifetime pack-years based on age of smoking initiation, periods of quitting and average lifetime cigarettes smoked per day. Reproducibility of these smoking variables has been previously reported.[@R11]

Echocardiographic protocol {#s2b}
--------------------------

Trained sonographers performed standard echocardiography examinations, including spectral, colour and tissue Doppler, M-mode, 2D imaging with harmonics, optimising depth and sector width to maintain a high frame rate.[@R9] All measures were performed by experienced sonographers at each field imaging centre as per American Society of Echocardiography (ASE) recommendations.[@R9]

Echocardiographic-measured and derived variables were used as follows: left ventricular mass (LVM) was determined from LV chamber size and wall thickness as per ASE guidelines. Relative wall thickness (RWT) was defined as 2\*(LV posterior wall thickness/LV internal diastolic diameter). Pulse-wave Doppler was performed with the sample volume placed at the level of the mitral leaflet tips to obtain peak early (E) diastolic transmitral inflow velocities; and tissue Doppler to acquire mitral early diastolic (e′) annular velocities (the average of septal and lateral annular velocities was used).[@R9] Left ventricular ejection fraction (LVEF) was derived from volumetric assessments to measure end-diastolic volume (EDV) and end-systolic volume (ESV) and calculated as follows: LVEF = (EDV − ESV) ⁄ EDV.[@R15]

Right ventricular (RV) end-diastolic area (RVAd) was measured via an RV-focused apical four-chamber view. Right ventricular fractional area change (RVFAC), tricuspid annular plane systolic excursion (TAPSE), right ventricular stroke volume (RVSV) and RV peak systolic (RV peak S) tissue Doppler velocity capture different dimensions of RV systolic function. RVFAC is defined as \[(RV end-diastolic area − RV end-systolic area)/RV end-diastolic area × 100\]. RVFAC was obtained by tracing the RV endocardium from the annulus, along the free wall to the apex, back to the apex, then along the interventricular septum. TAPSE was measured by placing an M-mode cursor through the tricuspid annulus and measuring longitudinal annulus motion. RVSV was assessed using right ventricular outflow tract (RVOT) dimensions and pulse-wave Doppler for RVOT velocity time integral (VTI). TR max (maximum) velocity was measured using continuous wave Doppler through the tricuspid valve as an assessment of RV systolic pressures.[@R16] Inter-reader reliability studies have been described and intraclass correlations were \>0.80 for all measures.[@R9]

Clinical characteristics {#s2c}
------------------------

The HCHS/SOL examination protocol has been previously published.[@R17] Trained and certified clinic staff obtained all demographic characteristics and medical history using interviewer-administered questionnaires, as well as blood samples and clinical measurements, on all HCHS/SOL participants. Medication use was assessed by participants bringing all medications and supplements used during the last 4 weeks. These were reviewed and coded by clinic staff. Diabetes was defined as[@R1]: fasting serum glucose \>126 mg/dL,[@R2] oral glucose tolerance test \>200 mg/dL,[@R3] self-reported diabetes,[@R4] glycosylated haemoglobin \>6.5%, or[@R5] taking antidiabetes medication or insulin. Height was measured to the nearest 0.1 cm and weight was measured to the nearest 0.1 kg with the use of a balance scale. Body mass index (BMI) was calculated as weight in kilograms divided by height in metres squared. After a 5 min rest, blood pressure was measured three times at 1 min intervals using an automated oscillometric device with the participant seated, using the average of the second and third blood pressure measurements. Hypertension was defined as a systolic blood pressure of [\>]{.ul}140 mm Hg, diastolic blood pressure of [\>]{.ul}90 mm Hg or on antihypertensive treatment. Coronary heart disease was defined as history of myocardial infarction or revascularisation as well as ECG evidence of old myocardial infarction. The prevalence of heart failure was assessed based on self-reported history of physician-diagnosed clinical heart failure. Chronic kidney disease was defined by an estimated glomerular filtration rate (eGFR) \<60 ml/min per 1.73 m^2^; GFR was estimated from serum creatinine.[@R19] Spirometry was conducted as previously described.[@R20] Participants with prebronchodilator forced expiratory volume/forced vital capacity ratios less than 0.70 or less than the lower limit of normal were defined as having airflow obstruction.

Statistical analysis {#s2d}
--------------------

Age, BMI, fasting glucose, heart rate, systolic and diastolic blood pressures, and total cholesterol are presented as continuous measures ± SE due to the survey weighting. Other variables were presented as proportional frequencies ± SEM. Mean measurements and SE of echocardiographic parameters according to smoking status were calculated using survey means. The association of smoking status (current vs never and former vs never) on echocardiographic measures was determined using survey linear regression. Nested multivariable linear regression models including sample weights based on survey statistics were used to describe the relationships between intensity and duration of tobacco usage (age at initiation of smoking, number of cigarettes per day on smoking days and pack-years) and echocardiographic indices of right and left ventricular structure and function. Multivariable models included age as a continuous variable with sex, BMI \<30 kg/m^2^, hypertension status and diabetes status as categorical variables. Multivariable analysis was performed for RV structural and functional indices stratified by having airflow obstruction. Survey regression was used to determine significant differences between some-days smokers versus daily smokers with mean echocardiographic parameters. For current smokers, unweighted means were calculated for age of smoking initiation, number of cigarettes smoked per day and number of pack-years. Further, stratified analysis was performed based on three classifications: diabetes only (n=27) excluding cases with hypertension, hypertension only (n=82) excluding cases with diabetes and healthy cases (n=96) excluding any diabetes, hypertension or obesity. All analyses were conducted using SAS V.9.4 (SAS Institute). SAS survey procedures and sampling weights were used to account for the complex survey design used in HCHS/SOL. A p value≤0.01 was considered statistically significant.

Results {#s3}
=======

ECHO-SOL included 1818 participants. Mean age of the ECHO-SOL target population in our analysis was 56.4 years and included 1187(57.4%) women. Mean BMI was 30.1. Only fewer than one-third (29.5%) did not have prediabetes or diabetes and half were hypertensive. Over 90% were without chronic kidney disease. Fifty-five per cent reported never smoking, 25.7% identified as former smokers and 17.7% identified as current smokers. Former smokers were older, less likely to be female, more likely to be hypertensive and diabetic than current smokers. Almost one-quarter were being treated with renin-angiotensin system (RAS) blockade. RAS blockade and beta blockers use was more common among former smokers compared with never or current smokers ([table 1](#T1){ref-type="table"}). Among the 304 current smokers, the median age of initiation was 17.0 years with the middle 50% ranging from 14 to 20 years old and \~5% who started smoking under the age of 12 ([figure 1](#F1){ref-type="fig"}). The median number of pack years was 16.0 with the middle 50% ranging from 6.4 to 31.0. The median number of cigarettes smoked per day was 10.0 (also the most frequently reported value) with the middle 50% ranging from 5 to 17 cigarettes per day.

![Histograms among current smokers.](openhrt-2017-000614f01){#F1}

###### 

Subject characteristics, ECHO-SOL (n=1818)

  Variable                           Total         Never         Former       Current
  ---------------------------------- ------------- ------------- ------------ ------------
  Age, years                         56.4±0.4      56.1 (0.5)    58 (0.5)     55 (0.6)
  Female, %                          57.4 (1187)   68.1(786)     42.4(238)    45.0 (163)
  Body mass index, mean (kg/m^2^)    30.1±0.2      30.6 (0.3)    30.0 (0.3)   29 (0.4)
  Fasting glucose                    106±1.1       105 (1.4)     109 (1.8)    108 (2.3)
  Heart rate (bpm)                   66±0.3        66 (0.4)      65 (0.6)     66 (0.7)
  Hypertension, %                    50 (861)      497 (49.4)    227 (52.9)   137 (47.9)
  Systolic BP (mm Hg)                136±0.6       137 (0.9)     137 (1.2)    134 (1.3)
  Diastolic BP (mm Hg)               78±0.4        78 (0.5)      78 (0.7)     78 (0.9)
  Total cholesterol (mg/dL)          209±1.4       210 (1.7)     210 (3.3)    201 (3.2)
  Chronic kidney disease, %          6.4 (106)     6.7 (65)      6.3 (24)     5.8 (17)
  Smoking status, %                                56.7 (1069)   25.7 (443)   17.6 (304)
    Current non-daily smokers                                                 19.1 (66)
    Current daily smokers                                                     80.9 (238)
  Diabetes status, %                                                          
    Non-diabetic                     29.5 (548)    325 (29.7)    133 (29.4)   89 (29.1)
    Prediabetic                      43.0 (747)    448 (42.1)    165 (39.7)   133 (45.2)
    Diabetic                         27.5 (523)    296 (28.2)    145 (30.9)   82 (25.7)
  Coronary heart disease, %          6.9 (108)     5.4 (54)      9.9 (33)     7.2 (21)
  Heart failure, %                   3.6 (49)      2.5 (26)      5.7 (13)     4.4 (10)
  ACE inhibitors, %                  312 (17.1)    191 (16.4)    76 (18.9)    45 (16.8)
  Angiotensin receptor blockers, %   140 (7.3)     79 (7.1)      50 (10.4)    11 (3.6)
  Beta blockers, %                   201 (12.1)    114 (10.9)    68 (18.2)    19 (6.9)

Data are presented as mean + SEM or % (unweighted N) using weighted row percentages. It is HCHS/SOL publication policy to present weighted percentages. Unweighted percentages can be calculated based on unweighted N's listed. Chronic kidney disease defined by eGFR \<60 ml/min.

BP, blood pressure; ECHO-SOL, Echocardiographic Study of Hispanics/Latinos; eGFR, estimated glomerular filtration rate; HCHS/SOL, Hispanic Community Health Study/Study of Latinos.

When compared with never smokers, former smokers were found to have significantly lower LVEF, RVOT VTI and LVM([table 2](#T2){ref-type="table"}, [figure 2](#F2){ref-type="fig"}). When compared with never smokers, current smokers had higher unadjusted mean LVEDV and LVESV, as well as significantly lower mean RV peak S velocity, TR max velocity, E/e′ ratio and TR max pressure gradients. In linear regression models ([table 3](#T3){ref-type="table"}), both current and former smokers were found to have decreased RVOT VTI when compared with never smokers. Former smoking status was associated with decreased LVEF, increased LVM and increased RVAd, whereas current smoking status was associated with a lower RV peak S wave velocity, RVOT VTI, E/e′ ratio, TR max pressure gradient and velocity. LVEDV and LVESV were increased in current smokers compared with never smokers.

![Unadjusted means by smoking status. EF, ejection fraction; LVEDV, left ventricular end-diastolic volume; LVESV, left ventricular end-systolic volume; LVM, left ventricular mass; RVAd, right ventricular area at diastole; RVFAC, right ventricular fractional area change; RVSV, right ventricular stroke volume.](openhrt-2017-000614f02){#F2}

###### 

Mean values of echocardiographic parameters according to smoking status

  Variable                                   Never smokers   Former smokers   Current smokers                                                                                               
  ------------------------------------------ --------------- ---------------- ----------------- ----------- ----------------- --------- ----------- ----------- ----------------- --------- ------------
  Left ventricular structure and function                                                                                                                                                   
   LVEDV, mL                                 81.9            36.0--168.0      0.4               85.0        31.2--200.7       1.5       0.09        **86.6**    **34.6--184.1**   **1.5**   **0.009**
   LVESV, mL                                 32.6            8.4--90.3        1.0               34.7        13.4--88.5        0.7       0.02        **36.4**    **12.9--137.1**   **1.0**   **0.001**
   LVEF, %                                   60.3            38.7--79.6       0.2               **59.4**    **36.3--73.4**    **0.3**   **0.01**    **58.7**    **17.3--95.7**    **0.7**   **0.01**
   LVM, g                                    149.7           63.6--469.6      2.3               **159.8**   **67.4--336.1**   **2.9**   **0.01**    156.8       60.3--325.6       2.9       0.09
   RWT                                       0.4             0.2--0.8         0.01              0.4         0.2--0.8          0.01      0.34        0.4         0.2--0.7          0.01      0.11
   E/e′                                      10.1            4.3--28.0        10.1              9.9         4.7--27.7         0.2       0.38        **9.5**     **4.5--28.0**     **0.5**   **0.008**
  Right ventricular structure and function                                                                                                                                                  
   RVAd, cm^2^                               14.5            4.9--29.0        0.2               **15.4**    **4.8--31.9**     **0.2**   **0.003**   15.1        5.9--28.0         0.3       0.06
   RVFAC                                     0.46            0.09--0.72       0.01              0.45        −0.1--0.7         0.01      0.30        0.4         0.1--0.7          0.01      0.03
   TAPSE, cm                                 2.1             0.9--3.5         0.03              2.1         0.8--3.4          0.03      0.52        2.0         0.5--3.3          0.04      0.08
   RV peak S velocity                        12.0            5.3--25.8        0.1               12.0        5.5--22.3         0.14      0.92        **11.4**    **3.6--20.2**     **0.2**   **0.009**
   RVOT VTI, cm                              17.8            8.7--30.6        0.2               **17.0**    **9.5--31.3**     **0.2**   **0.005**   **16.7**    **6.8--27.7**     **0.2**   **0.0002**
   RVSV, mL                                  49.3            13.9--141.4      0.9               48.3        14.0--117.4       1.3       0.51        45.7        10.4--120.5       1.3       0.02
   TR max peak gradient, mm Hg               18.3            0.1--3.3         0.02              18.1        1.6--42.5         0.5       0.67        **16.2**    **1.5--44.8**     **0.5**   **0.0003**
   TR max velocity, cm/s                     209.1           11.1--329.2      2.0               207.5       63.3--325.8       3.1       0.63        **195.7**   **60.2--334.5**   **3.2**   **0.0003**

Bold denotes statistically significant associations (p≤0.01).

E/e′, transmitral E velocity to mitral annulus e′ velocity; LVEDV, left ventricular end-diastolic volume; LVEF, left ventricular ejection fraction; LVESV, left ventricular end-systolic volume; LVM, left ventricular mass; RVAd, right ventricular area at diastole; RVFAC, right ventricular fractional area change; RVOT, right ventricular outflow tract; RVSV, right ventricular stroke volume; RWT, relative wall thickness; TAPSE, tricuspid annular plane systolic excursion; TR, tricuspid regurgitation; VTI, velocity time integral.

###### 

Regression coefficients for former or current smokers compared with never smokers

  Variable                                   Former versus never   Current versus never               
  ------------------------------------------ --------------------- ---------------------- ----------- ------------
  Left ventricular structure and function                                                             
   LVEDV, mL                                 3.09                  0.09                   **4.74**    **0.0088**
   LVESV, mL                                 2.077                 0.016                  **3.79**    **0.0008**
   LVEF, %                                   **−0.9**              **0.010**              −0.166      0.013
   LVM, g                                    **10.17**             **0.009**              6.41        0.09
   RVAd, cm2                                 **0.88**              **0.003**              0.63        0.06
   RWT                                       0.007                 0.34                   −0.011      0.11
   E/e′                                      −0.21                 0.38                   **−0.67**   **0.008**
  Right ventricular structure and function                                                            
   RVFAC                                     −0.01                 0.30                   −0.02       0.03
   TAPSE, cm                                 −0.02                 0.51                   −0.07       0.08
   RV peak S velocity, cm/s                  0.02                  0.92                   **−0.65**   **0.009**
   RVOT VTI, cm                              **−0.8**              **0.005**              **−1.15**   **0.0002**
  RVSV, mL                                   −1.03                 0.51                   −3.65       0.02
   TR max peak gradient, mm Hg               −0.22                 0.67                   **−2.06**   **0.0003**
   TR max velocity, cm/s                     −1.57                 0.63                   **−13.4**   **0.0003**

Bold denotes statistically significant associations (p≤0.01)

E/e′, transmitral E velocity to mitral annulus e′ velocity; LVEDV, left ventricular end-diastolic volume; LVEF, left ventricular ejection fraction; LVESV, left ventricular end-systolic volume; LVM, left ventricular mass; RVAd, right ventricular area at diastole; RVFAC, right ventricular fractional area change; RVOT, right ventricular outflow tract; RVSV, right ventricular stroke volume; RWT, relative wall thickness; TAPSE, tricuspid annular plane systolic excursion; TR, tricuspid regurgutation; VTI, velocity time integral.

Among current smokers, significant differences were seen for the mean ages of initiation among those with normal versus abnormal diastolic function and RVSV; for the mean number of cigarettes per day between those with normal versus abnormal diastolic function, RVSV and LVM; and for the mean number of pack-years among those with normal versus abnormal diastolic function, RVFAC, RVSV, TAPSE and LVM ([figure 3](#F3){ref-type="fig"}). In multivariable-adjusted models (age, sex, obesity status, hypertension status and diabetes status) ([table 4](#T4){ref-type="table"}), among current smokers, increased duration of smoking as measured by lower age of smoking initiation was significantly associated with higher LVM. Lower age of initiation was associated with lower RVSV, higher TR max velocity and lowerE/e′ ratio. The number of cigarettes smoked per day was associated with a higher LVM, RWT, TR max velocity, E/e′ ratio, TR max pressure gradient, and with a lower RVSV and RVOT VTI. Increasing lifetime pack-years was associated with higher LVM, E/e′ ratio and RWT. Conversely, increasing lifetime pack-years was also associated with lower RVFAC, lower TAPSE, lower RV peak S and lower RVSV.

![Unadjusted means according to normal versus abnormal cardiac variables among current smokers. DD, diastolic dysfunction; LVM, left ventricular mass; RVFAC, right ventricular fractional area change; RVSV, right ventricular stroke volume; RWT, relative wall thickness; TAPSE, tricuspid annular plane systolic excursion.](openhrt-2017-000614f03){#F3}

###### 

Multivariate analysis of different measures of tobacco usage

  Variable                                   Age at initiation   Cigarettes per day   Lifetime pack-years                                
  ------------------------------------------ ------------------- -------------------- --------------------- -------------- ------------- --------------
  Left ventricular structure and function                                                                                                
   LVEDV, mL                                 0.15                0.03                 0.03                  0.46           −0.02         0.16
   LVESV, mL                                 0.059               0.05                 0.014                 0.52           −0.01         0.18
   LVEF, %                                   −0.002              0.87                 −0.004                0.80           −0.002        0.51
   LVM, g                                    **−0.29**           **0.01**             **0.58**              **\<**0.0001   **0.33**      **\<**0.0001
   RVAd, cm^2^                               0.02                0.24                 0.002                 0.85           0.0008        0.76
   RWT                                       −0.00009            0.82                 **0.003**             **\<**0.0001   **0.0007**    **\<**0.0001
   E/e′                                      **0.03**            **0.001**            **0.046**             **\<**0.0001   **0.009**     **0.0006**
  Right ventricular structure and function                                                                                               
   RVFAC                                     −0.0007             0.14                 −0.0003               0.12           **−0.0006**   **\<**0.0001
   TAPSE, cm                                 0.00004             0.98                 −0.0005               0.68           **−0.0015**   **\<**0.0001
   RV peak S                                 −0.017              0.03                 **0.017**             **0.0001**     **−0.007**    **\<**0.0001
   RVOT VTI, cm                              **0.05**            **0.0002**           **−0.025**            **0.0009**     **−0.014**    **\<**0.0001
   RVSV, mL                                  **0.63**            **\<**0.0001         **−0.28**             **\<**0.0001   **−0.07**     **\<**0.0001
   TR max peak gradient, mm Hg               0.035               0.06                 **0.098**             **\<**0.0001   −0.01         0.02
   TR max velocity, cm/s                     **0.36**            **0.005**            **0.68**              **\<**0.0001   −0.05         0.16

Adjusted for age, sex, hypertension, diabetes and BMI.

Bold denotes statistically significant associations (p≤0.01).

BMI, body mass index; E/e′, transmitral E velocity to mitral annulus e′ velocity; LVEDV, left ventricular end-diastolic volume; LVEF, left ventricular ejection fraction; LVESV, left ventricular end-systolic volume; LVM, left ventricular mass; RVAd, right ventricular area at diastole; RVFAC, right ventricular fractional area change; RVOT, right ventricular outflow tract; RVSV, right ventricular stroke volume; RWT, relative wall thickness; TAPSE, tricuspid annular plane systolic excursion; TR, tricuspid regurgitation; VTI, velocity time integral.

Among current smokers, 19.1% were some-days smokers. Unadjusted mean values of echocardiographic parameters were compared between current smokers who smoked daily and those who were non-daily smokers ([table 5](#T5){ref-type="table"}). Daily smokers were found to have lower LVEF and impaired indices of RV function (TAPSE, RV peak S velocity, RVOT VTI, TR max peak gradient) along with higher mean LVM and E/e′ ratio compared with non-daily smokers. Among those with measured airway obstruction, defined by abnormal spirometry, increasing smoking intensity and duration (younger age of initiation, increasing cigarettes per day and pack-years) was associated with decreasing RVSV ([table 6](#T6){ref-type="table"}). Among those with no airflow obstruction, a significant negative association emerged for increasing cigarettes per day with lower RVAd, RVFAC and TAPSE. TR max velocity and pressure gradient increased with cigarettes per day in both strata. Increasing pack-years was associated with decreased RVFAC, RVOT VTI and RVSV in both strata.

###### 

Means of current smokers (daily smokers versus non-daily smokers)

  Variable                                   Non-daily smokers   Daily smokers                          
  ------------------------------------------ ------------------- --------------- ----------- ---------- --------------
  Left ventricular structure and function                                                               
   LVEDV, mL                                 85.5                3.6             86.9        1.6        0.43
   LVESV, mL                                 35.1                1.9             36.7        1.1        0.08
   LVEF, %                                   **60**              **1.0**         **58.4**    **0.7**    **\<**0.0001
   LVM, g                                    **148.1**           **4.0**         **158.0**   **3.4**    **\<**0.0001
   RWT                                       0.4                 0.01            0.39        0.01       0.017
   E/e′                                      **8.8**             **0.3**         **9.6**     **0.3**    **\<**0.0001
  Right ventricular structure and function                                                              
   RVAd, cm^2^                               14.9                0.6             15.2        0.3        0.3
   RVFAC                                     0.45                0.01            0.44        0.01       0.07
   TAPSE, cm                                 **2.2**             **0.05**        **2.01**    **0.04**   **\<**0.0001
   RV peak S velocity, cm/s                  **12.2**            **0.4**         **11.2**    **0.2**    **\<**0.0001
   RVOT VTI, cm                              **17.5**            **0.4**         **16.5**    **0.3**    **\<**0.0001
   Right ventricular stroke volume, mL       46.6                2.2             45.5        1.5        0.4
   TR max peak gradient, mm Hg               **17.3**            **1.1**         **15.9**    **0.6**    **0.0017**
   TR max velocity, cm/s                     **201.9**           **7.6**         **194.2**   **3.8**    **0.01**

Bold denotes statistically significant associations (p≤0.01).

E/e′, transmitral E velocity to mitral annulus e′ velocity; LVEDV, left ventricular end-diastolic volume; LVEF, left ventricular ejection fraction; LVESV, left ventricular end-systolic volume; LVM, left ventricular mass; RVAd, right ventricular area at diastole; RVFAC, right ventricular fractional area change; RVOT, right ventricular outflow tract; RWT, relative wall thickness; TAPSE, tricuspid annular plane systolic excursion; Tr, tricuspid regurgitation; VTI, velocity time integral.

###### 

Multivariate analysis of right ventricular structure and function stratified by obstructive lung disease status

  Variable                               Age of initiation   Cigarettes per day   Pack-years                                
  -------------------------------------- ------------------- -------------------- ------------ -------------- ------------- --------------
  **No airflow obstruction**                                                                                                
  RVAd, cm^2^                            0.011               0.54                 0.032        0.0191         0.001         0.87
  RVFAC                                  −0.002              0.0008               0.0002       0.50           **−0.0004**   **\<**0.0001
  TAPSE, cm                              −0.001              0.60                 **0.005**    **0.0089**     −0.0003       0.46
  RV peak S velocity, cm/s               −0.032              0.0004               0.029        \<0.0001       −4.3E-05      0.98
  RVOT VTI, cm                           **0.070**           **\<**0.0001         −0.007       0.0137         **−0.011**    **0.0012**
  Right  ventricular stroke volume, mL   **0.716**           **\<**0.0001         −0.193       0.0152         **−0.086**    **0.0001**
  TR max velocity, cm/s                  **0.003**           **0.0021**           **0.005**    **0.0049**     −0.0003       0.62
  TR max PG, mm Hg                       0.020               0.19                 **0.065**    **0.0065**     −0.004        0.66
  **Airflow obstruction**                                                                                                   
  RVAd, cm^2^                            0.069               0.11                 **−0.063**   **\<**0.0001   0.010         0.07
  RVFAC                                  **0.006**           **0.0003**           **−0.001**   **0.0019**     **−0.001**    **\<**0.0001
  TAPSE, cm                              **0.019**           **\<**0.0001         **−0.010**   **\<**0.0001   **−0.003**    **\<**0.0001
  RV peak S velocity, cm/s               0.023               0.29                 −0.004       0.5073         **−0.009**    **\<**0.0001
  RVOT VTI, cm                           0.082               0.024                **−0.070**   **\<**0.0001   **−0.035**    **\<**0.0001
  Right ventricular stroke volume, mL    **1.269**           **0.001**            **−0.456**   **\<**0.0001   **−0.144**    **\<**0.0001
  TR max velocity, cm/s                  **0.023**           **0.0005**           **0.006**    **\<**0.0001   **0.002**     **\<**0.0001
  TR max PG, mm Hg                       **0.390**           **0.001**            **0.091**    **\<**0.0001   **0.029**     **0.0003**

Bold denotes statistically significant associations (p≤0.01).

PG, peak gradient; RVAd, right ventricular area at diastole; RVFAC, right ventricular fractional area change; RVOT, right ventricular outflow tract; TAPSE, tricuspid annular plane systolic excursion; TR, tricuspid regurgitation; VTI, velocity time integral.

When those with coronary heart disease or heart failure were excluded, all the relationships for LVM and RVSV remained the same across all measurements of cigarette use. Additionally, there was no change in the impact that age of initiation had on RVOT VTI, E/e′ ratio and TR max velocity. Significant associations of younger age of initiation with decreasing LVEDV, LVESV and TR max pressure gradient, as well as increasing cigarettes per day with increasing LVESV emerged. The associations between cigarettes per day and RV peak S, and RVOT VTI, as well as pack-years with TAPSE lost statistical significance (data not shown). Stratified analysis showed consistent and diffuse alterations of RV and LV structure and function with different measures of tobacco usage most pronounced among diabetics and less so among those only hypertensive, or among only the healthy (see online [supplemental table](#SP1){ref-type="supplementary-material"}).
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###### Supplementary Table 1

Discussion {#s4}
==========

There were a number of observed dose--response relationships between intensity and duration of cigarette smoking with measures of right and left cardiac structure and function. Among current smokers, increased duration of smoking (as measured by younger age of initiation) was associated with worse measures of LV structure (increasing mass and RWT), worse LV diastolic function and worse measures of RV function (RVSV, RVFAC). Increasing number of cigarettes smoked per day was associated with increasing LVM, worse diastolic function, worse LV geometry and worse RV function. Lastly, increasing lifetime pack-years was associated with increasing LVM, worse LV geometry, worse diastolic function, more RV dilation and worse RV function.

Tobacco smoke is a complicated mixture of over 5000 compounds.[@R21] Cigarette smoking can exert adverse cardiac effects through a number of different pathways.[@R22] Although the relationship between smoking and atherosclerotic cardiovascular disease has been well demonstrated, the exact mechanisms through which smoking acts are myriad and incompletely defined.[@R23] Proposed mechanisms for adverse cardiovascular outcomes include increased sympathetic stimulation via nicotine, carbon monoxide exposure, endothelial dysfunction, direct cellular toxicity and oxidative stress which accelerates atherosclerosis and has prothrombotic effects.[@R23] In animal models, tobacco smoke has been shown to induce ventricular hypertrophy and remodelling with associated increases in serum norepinephrine levels, nicotinamide adenine dinucleotide phosphate oxidase activity and mitogen-activated protein kinase activation.[@R24] This suggests that smoking also causes cardiac damage at the microcellular level independent of atherosclerotic and thrombotic events. Smoking has a known association with increased arterial stiffness.[@R26] The active ingredient in the chemical addiction to cigarettes, nicotine, directly stimulates the autonomic nervous system and increases sympathetic outflow.[@R27] Acute exposure to nicotine has been found to increase heart rate, myocardial contractility and blood pressure.[@R30] By inducing a chronic state of sympathetic activity, usage of cigarettes has the potential to cause chronic micro-increases in blood pressure; arterial stiffness and heart rate can induce cardiac remodelling, increase LVM and potentially lead to cardiomyopathy. With cardiac hypertrophy, impaired diastolic function would be expected. Further, smoking-related micro-alterations resulting in higher heart rate and blood pressure would increase myocardial oxygen demand, making the heart more susceptible to microvascular ischaemic damage. Such a proposed model could explain why we observed abnormalities in LV mass, LV geometry and diastolic function related to increased cigarette smoke in the absence of known clinical coronary arterial disease.

While much of the epidemiologic research on the cardiovascular effects of smoking has focused on atherosclerotic disease, few work has examined cardiac functional aspects. The effects of nicotine on cardiac function have been studied using snus, a form of smokeless tobacco. Otherwise, healthy regular snus users considered free of cardiovascular disease had no significant change in systolic parameters but did have a prolonged deceleration times compared with non-nicotine users.[@R31] Acute nicotine exposure was also found to cause a significant decrease and delay in relaxation of both right and left ventricles.[@R32] Studies in healthy subjects have demonstrated acute impairment of LV diastolic function and inducement of a hyperdynamic RV in response to smoking a single cigarette.[@R33] Smoking is also a risk factor for coronary spasm both in the presence and absence of atherosclerotic coronary artery disease.[@R34] This may be due to the decreased nitric oxide generation which has been found in smokers with impaired endothelium-dependent vasodilation.[@R36] Decreased nitric oxide activity has also been observed in the coronary arteries of smokers.[@R37] All of these pathways combine to form an environment where the myocardium may be more susceptible to microvascular insults, leading to chronic damage and fibrosis affecting both cardiac structure and function. Many of these mechanisms have also been implicated in smoking as an inducer of chronic kidney disease.[@R38] Our observed relationships may be the result of microvascular or inflammatory insults on the myocardium, sympathetic stimulation, coronary vasoconstriction, oxidative stress or toxic chemical exposure. Of course, the injury models described here would have effects on the LV and potentially on the RV.

The inclusion of comprehensive right heart echocardiography is important when studying the cardiac effects of tobacco. Prior studies of the cardiac alterations of smoking did not include assessment of the right heart or pulmonary function. Our study employed multiple measures of right heart function (RVFAC, RV peak S, RVSV and TAPSE) and found that altered RV function was associated with more cigarettes smoked and that this association was more consistent among those with impairment of lung function. The RV may be involved in whatever ischaemic or myopathic process is being imparted on the LV, helping to explain our findings of impaired RV function with increasing cigarette usage. Cigarette smoking is also the most common risk factor for development of chronic obstructive pulmonary disease (COPD).[@R39] COPD is associated with increased blood pressures in the pulmonary circuit[@R40] and RV enlargement, LV enlargement, as well as LV systolic and diastolic dysfunction.[@R41] Even subclinical impairment of lung function has been shown to be associated with LV systolic and diastolic dysfunction[@R42] which could potentially contribute to RV dysfunction as well.

Prior studies of the cardiac effects of tobacco were mostly racially homogenous and did not include Hispanics. To our knowledge, this is one of the first studies evaluating the association of exposure to smoking using measures of smoking intensity and duration (cigarettes per day, age of smoking initiation and lifetime pack-years of smoking) with comprehensive measures of cardiac structure and function including RV parameters and LV diastolic function in Hispanics/Latinos. Prior studies were mostly racially homogenous and did not include Hispanics/Latinos; they were 'piecemeal' in their assessment of cardiac structure and function whereas we provided a single comprehensive assessment. Further, compared with the report from the Atherosclerosis Risk in Communities study,[@R43] our population is significantly younger by an average of 20 years with an average 16 lower pack-years of smoking but nevertheless showed the adverse cardiomyopathic effects of smoking intensity and duration. An important implication of our study is that cigarette smoking exposure may impact the development of cardiomyopathy in a direct, continuous fashion. The potential contribution of tobacco exposure to cardiomyopathy development and to the ongoing heart failure epidemic deserves further study and public health vigilance.

This study has some limitations. Our study was cross-sectional study and observational, hence we cannot exclude residual confounding, we cannot assess for temporality of the relations, and we cannot establish a causal relation between smoking and the echocardiographic measures. While it is advantageous to collect many structural and functional indices to paint a more complete picture, it carries the issue of multiple testing and type I error. To compensate for this, we set a more rigorous p value at 0.01. Finally, there may be differential responses to chronic cigarette use based on race or ethnicity which may limit the generalisability of our results.

Our study provides evidence that there are cardiac abnormalities of structure and function associated with the intensity and duration of cigarette use in a relatively young cohort. Many of these relationships persisted even after excluding those with known coronary artery disease or heart failure. Our results imply that patients are likely damaging their hearts in a measurable fashion by smoking even if they have not suffered a clinical cardiovascular event. Descriptions of these cardiac abnormalities could serve as important data points for clinicians to use when counselling their patients on tobacco cessation. Traditionally, pack-years has been a standard clinical history assessment of total tobacco exposure. Our results are evidence that indices of both duration and intensity of usage are associated with abnormalities in multiple echocardiographic measures involving both the right and the left sides of the heart. From a research standpoint, more comprehensive assessments of tobacco or nicotine product usage should be used in future cohorts.
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